Trestolone

Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by injection into muscle.

Medical uses

Trestolone is an experimental medication and is not currently approved for medical use. It has been under development for potential use as a male hormonal contraceptive and in androgen replacement therapy for low testosterone levels. The medication has been studied and developed for use as a subcutaneous implant. An androgen ester and prodrug of trestolone, trestolone acetate, has also been developed, for use via intramuscular injection. ==Side effects==

Side effects

Trestolone may cause sexual dysfunction (e.g., decreased sex drive, reduced erectile function) and decreased bone mineral density due to estrogen deficiency. ==Pharmacology==

Pharmacology

Pharmacodynamics As an AAS, trestolone is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and dihydrotestosterone (DHT). As such, it has a high ratio of anabolic to androgenic activity, similarly to other nandrolone derivatives. However, trestolone has only weak estrogenic activity and an amount that would appear to be insufficient for replacement purposes, as evidenced by decreased bone mineral density in men treated with it for hypogonadism. As such, trestolone must be administered parenterally via a different and more practical route such as subcutaneous implant, transdermal patch, or topical gel. Trestolone acetate, a prodrug of trestolone, can be administered via intramuscular injection. ==Chemistry==

Chemistry

Trestolone, also known as 7α-methyl-19-nortestosterone (MENT) or as 7α-methylestr-4-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of nandrolone (19-nortestosterone). Trestolone is an intermediate used in the synthesis of mibolerone, tibolone & isotibolone. If it is oxidized to mentabolan, this in-turn can be used to synthesize almestrone, a compound with manifold steroid synthesis applications. ==History==

History

Trestolone was first described in 1963. However, it was not subsequently studied again until 1990. Development of trestolone for potential use in male hormonal contraception and androgen replacement therapy was started by 1993, and continued thereafter. No additional development appears to have been conducted since 2013. Trestolone was developed by the Population Council, a non-profit, non-governmental organization dedicated to reproductive health. ==Society and culture==

Society and culture

Generic names Trestolone is the generic name of the drug and its . It is also commonly known as 7α-methyl-19-nortestosterone (MENT). ==References==

Source: Wikipedia ↗

tickerdossier.com tickerdossier.substack.com